Leukemia & Lymphoma, Volume 53, Issue 5 (2012)

Browse this journal
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Leukemia & Lymphoma, Volume 53, Issue 5 (2012)

See all volumes and issues
Vol 65, 2024 Vol 64, 2023 Vol 63, 2022 Vol 62, 2021 Vol 61, 2020 Vol 60, 2019 Vol 59, 2018 Vol 58, 2017 Vol 57, 2016 Vol 56, 2015 Vol 55, 2014 Vol 54, 2013 Volume 53, 2012 Vol 52, 2011 Vol 51, 2010 Vol 50, 2009 Vol 49, 2008 Vol 48, 2007 Vol 47, 2006 Vol 46, 2005 Vol 45, 2004 Vol 44, 2003 Vol 43, 2002 Vol 42, 2001 Vol 41, 2001 Vol 40, 2000-2001 Vol 39, 2000 Vol 38, 2000 Vol 37, 2000 Vol 36, 1999-2000 Vol 35, 1999 Vol 34, 1999 Vol 33, 1999 Vol 32, 1998-1999 Vol 31, 1998 Vol 30, 1998 Vol 29, 1998 Vol 28, 1997-1998 Vol 27, 1997 Vol 26, 1997 Vol 25, 1997 Vol 24, 1996-1997 Vol 23, 1996 Vol 22, 1996 Vol 21, 1996 Vol 20, 1995-1996 Vol 19, 1995 Vol 18, 1995 Vol 17, 1995 Vol 16, 1995 Vol 15, 1995 Vol 16, 1995 Vol 15, 1995 Vol 14, 1994 Vol 13, 1994 Vol 12, 1993-1994 Vol 11, 1993 Vol 10, 1993 Vol 9, 1993 Vol 8, 1992 Vol 7, 1992 Vol 6, 1991-1992 Vol 5, 1991 Vol 4, 1991 Vol 3, 1990-1991 Vol 2, 1990 Vol 1, 1989-1990
Download citations Download PDFs

Commentary on selected articles in this issue

Article Commentary
Special delivery: getting radiation to the target in diffuse large B-cell lymphoma
Andrew Wirth & Michael S. Hofman
Pages: 751-753
Published online: 09 Apr 2012
First Page PreviewforSpecial delivery: getting radiation to the target in diffuse large B-cell lymphoma | Full Text | References | PDF (137.8 KB) | Supplemental
  • 514 Views
  • 0 CrossRef citations
  • 0Altmetric
Free Access

Commentary

Article Commentary
Is autologous stem cell transplantation for transformed follicular lymphoma still justifiable?
Michael Dickinson
Pages: 754-755
Published online: 13 Feb 2012
CitationforIs autologous stem cell transplantation for transformed follicular lymphoma still justifiable? | Full Text | References | PDF (223.5 KB) | Supplemental
  • 1007 Views
  • 2 CrossRef citations
  • 0Altmetric
Free Access
Article Commentary
Salvage chemotherapy and autologous hematopoietic cell transplant in primary refractory diffuse large B-cell lymphoma: progress or better patient selection?
Ashley Rosko & Hillard M. Lazarus
Pages: 756-757
Published online: 16 Jan 2012
CitationforSalvage chemotherapy and autologous hematopoietic cell transplant in primary refractory diffuse large B-cell lymphoma: progress or better patient selection? | Full Text | References | PDF (221.1 KB) | Supplemental
  • 637 Views
  • 0 CrossRef citations
  • 0Altmetric
Free Access
Article Commentary
Fourteen-day rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP-14): use it right or do not use it at all
Carsten Zwick & Michael Pfreundschuh
Pages: 758-759
Published online: 13 Feb 2012
CitationforFourteen-day rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP-14): use it right or do not use it at all | Full Text | References | PDF (217.8 KB) | Supplemental
  • 836 Views
  • 0 CrossRef citations
  • 0Altmetric
Free Access
Article Commentary
Predicting the outcome of patients with higher-risk myelodysplastic syndrome treated with hypomethylating agents
Raphael Itzykson & Pierre Fenaux
Pages: 760-762
Published online: 31 Jan 2012
First Page PreviewforPredicting the outcome of patients with higher-risk myelodysplastic syndrome treated with hypomethylating agents | Full Text | References | PDF (233.4 KB) | Supplemental
  • 919 Views
  • 4 CrossRef citations
  • 0Altmetric
Free Access

Review

Review Article
Clinical implications of the molecular subtypes of diffuse large B-cell lymphoma
Brian T. Hill & John Sweetenham
Pages: 763-769
Published online: 05 Jan 2012
AbstractforClinical implications of the molecular subtypes of diffuse large B-cell lymphoma | Full Text | References | PDF (396.6 KB) | Supplemental
  • 995 Views
  • 13 CrossRef citations
  • 0Altmetric

Review Article

Review Article
Maintenance rituximab in follicular non-Hodgkin lymphoma: facts and controversies
Chadi Nabhan, Sonali M. Smith & Brad S. Kahl
Pages: 770-778
Published online: 24 Oct 2011
AbstractforMaintenance rituximab in follicular non-Hodgkin lymphoma: facts and controversies | Full Text | References | PDF (283.8 KB) | Supplemental
  • 810 Views
  • 5 CrossRef citations
  • 0Altmetric
Review Article
A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q − myelodysplastic syndromes
Ioannis A. Voutsadakis & Anne Cairoli
Pages: 779-788
Published online: 25 Nov 2011
AbstractforA critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q − myelodysplastic syndromes | Full Text | References | PDF (426.9 KB) | Supplemental
  • 519 Views
  • 10 CrossRef citations
  • 0Altmetric
Review Article
Overview of alemtuzumab therapy for the treatment of T-cell lymphomas
Pier Luigi Zinzani, Paolo Corradini, Andrea Gallamini, Alberto Grossi, Mario Lazzarino, Monia Marchetti, Maurizio Martelli, Giuseppe Rossi & Umberto Vitolo
Pages: 789-795
Published online: 18 Nov 2011
AbstractforOverview of alemtuzumab therapy for the treatment of T-cell lymphomas | Full Text | References | PDF (274.1 KB) | Supplemental
  • 501 Views
  • 12 CrossRef citations
  • 0Altmetric
Review Article
MyelomA Genetics International Consortium
Gareth Morgan, Hans Erik Johnsen, Hartmut Goldschmidt, Antonio Palumbo, Michele Cavo, Pieter Sonneveld, Jesus San Miguel, Char Sang Chim, Paul Browne, Hermann Einsele, Anders Waage, Ingemar Turesson, Andrew Spencer, Roman Hajek, Heinz Ludwig, Kari Hemminki & Richard Houlston
Pages: 796-800
Published online: 03 Jan 2012
AbstractforMyelomA Genetics International Consortium | Full Text | References | PDF (269.2 KB) | Supplemental
  • 447 Views
  • 7 CrossRef citations
  • 0Altmetric

Original Articles: Clinical

Article
Doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy with interferon for advanced stage classic Hodgkin lymphoma: a 10-year follow-up study
Nicolas Batty, Fredrick B. Hagemeister, Lei Feng, Jorge E. Romaguera, Maria A. Rodriguez, Peter McLaughlin, Felipe Samaniego, Amanda Copeland, Bouthaina S. Dabaja & Anas Younes
Pages: 801-806
Published online: 03 Jan 2012
AbstractforDoxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy with interferon for advanced stage classic Hodgkin lymphoma: a 10-year follow-up study | Full Text | References | PDF (350.7 KB) | Supplemental
  • 271 Views
  • 6 CrossRef citations
  • 0Altmetric

Research Article

Article
Pilot trial of yttrium-90 ibritumomab tiuxetan consolidation following rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone chemotherapy in patients with limited-stage, bulky diffuse large B-cell lymphoma
Deok-Hwan Yang, Won Seog Kim, Seok Jin Kim, Jin Seok Kim, Jae-Yong Kwak, Joo Seop Chung, Sung Yong Oh, Cheolwon Suh & Je-Jung Lee
Pages: 807-811
Published online: 07 Dec 2011
AbstractforPilot trial of yttrium-90 ibritumomab tiuxetan consolidation following rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone chemotherapy in patients with limited-stage, bulky diffuse large B-cell lymphoma | Full Text | References | PDF (280.8 KB) | Supplemental
  • 328 Views
  • 10 CrossRef citations
  • 0Altmetric
Article
Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series
Pablo Guisado-Vasco, Reyes Arranz-Saez, Miguel Canales, Araceli Cánovas, José Garcia-Laraña, Ramón García-Sanz, Andrés Lopez, José Luis López, Marta Llanos, José Maria Moraleda, José Rodriguez, Consuelo Rayón, Pilar Sabin, Antonio Salar, Ana Marín-Niebla, Manuel Morente, Pedro Sánchez-Godoy, José Francisco Tomás, Alfonso Muriel, Victor Abraira, Miguel A. Piris, Juán F. Garcia, Carlos Montalban & for the Spanish Hodgkin Lymphoma Study Group
Pages: 812-819
Published online: 31 Jan 2012
AbstractforStage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series | Full Text | References | PDF (488.2 KB) | Supplemental
  • 236 Views
  • 13 CrossRef citations
  • 0Altmetric
Article
The value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: a systematic review and qualitative analysis of the literature
Stéphane Lepretre, Uli Jäger, Ann Janssens, Veronique Leblond, Eugene Nikitin, Tadeusz Robak & Clemens-Martin Wendtner
Pages: 820-829
Published online: 13 Dec 2011
AbstractforThe value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: a systematic review and qualitative analysis of the literature | Full Text | References | PDF (413.2 KB) | Supplemental
  • 639 Views
  • 4 CrossRef citations
  • 0Altmetric
Article
High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era
Makiko Ban-Hoefen, Jennifer L. Kelly, Steven H. Bernstein, Jane Liesveld, Louis Constine, Michael Becker, Laurie Milner, Gordon Phillips & Jonathan W. Friedberg
Pages: 830-835
Published online: 06 Dec 2011
AbstractforHigh-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era | Full Text | References | PDF (333.1 KB) | Supplemental
  • 437 Views
  • 32 CrossRef citations
  • 0Altmetric
Article
Salvage chemotherapy and autologous stem cell transplant in primary refractory diffuse large B-cell lymphoma: outcomes and prognostic factors
David Telio, Kim Fernandes, Clement Ma, Richard Tsang, Armand Keating, Michael Crump & John Kuruvilla
Pages: 836-841
Published online: 05 Dec 2011
AbstractforSalvage chemotherapy and autologous stem cell transplant in primary refractory diffuse large B-cell lymphoma: outcomes and prognostic factors | Full Text | References | PDF (361.2 KB) | Supplemental
  • 1054 Views
  • 30 CrossRef citations
  • 0Altmetric
Article
Long-term outcome for immune suppression and immune related lymphoproliferative disorder: prospective data from the United Kingdom Children's Leukaemia and Cancer Group registry 1994–2004
Mary M. Taj, Nedim Hadzic, Susan E. Height, Andrew Wotherspoon, Margaret Burke, Rachel Hobson, Maria Viskaduraki & C. Ross Pinkerton
Pages: 842-848
Published online: 13 Dec 2011
AbstractforLong-term outcome for immune suppression and immune related lymphoproliferative disorder: prospective data from the United Kingdom Children's Leukaemia and Cancer Group registry 1994–2004 | Full Text | References | PDF (507.1 KB) | Supplemental
  • 205 Views
  • 6 CrossRef citations
  • 0Altmetric
Article
High thymidine kinase activity is a strong predictive factor for poor prognosis in peripheral T-cell lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone
Kazuhito Suzuki, Yasuhito Terui, Kenji Nakano, Eriko Nara, Kentaro Nasu, Kyoko Ueda, Noriko Nishimura, Yuko Mishima, Sakura Sakajiri, Masahiro Yokoyama, Shunji Takahashi & Kiyohiko Hatake
Pages: 849-854
Published online: 31 Oct 2011
AbstractforHigh thymidine kinase activity is a strong predictive factor for poor prognosis in peripheral T-cell lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone | Full Text | References | PDF (278.6 KB) | Supplemental
  • 125 Views
  • 2 CrossRef citations
  • 0Altmetric
Article
The extent of cutaneous lesions predicts outcome in extranodal nasal-type natural killer/T-cell lymphoma of the upper aerodigestive tract with secondary cutaneous involvement
Shu-Nan Qi, Ye-Xiong Li, Wei-Hu Wang, Jing Jin, Shu-Lian Wang, Yue-Ping Liu, Yong-Wen Song, Hui Fang, Hua Ren, Ning-Ning Lu, Qing-Feng Liu, Run-Ye Wu, Xi-Mei Zhang, Xin-Fan Liu & Zi-Hao Yu
Pages: 855-861
Published online: 13 Dec 2011
AbstractforThe extent of cutaneous lesions predicts outcome in extranodal nasal-type natural killer/T-cell lymphoma of the upper aerodigestive tract with secondary cutaneous involvement | Full Text | References | PDF (338.6 KB) | Supplemental
  • 164 Views
  • 11 CrossRef citations
  • 0Altmetric
Article
Upfront thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation for primary CNS lymphoma: a single centre experience
Nimira Alimohamed, Andrew Daly, Carolyn Owen, Peter Duggan & Douglas A. Stewart
Pages: 862-867
Published online: 06 Dec 2011
AbstractforUpfront thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation for primary CNS lymphoma: a single centre experience | Full Text | References | PDF (281 KB) | Supplemental
  • 934 Views
  • 49 CrossRef citations
  • 0Altmetric
Article
Molecular detection of circulating Sezary cells in patients with mycosis fungoides: could it predict future development of secondary Sezary syndrome? A single-institution experience
Charles Blake Hutchinson, Maggie Stoecker, Frances F. Wang, John Papalas, Siby Sebastian, James Burchette, Michael Datto & Endi Wang
Pages: 868-877
Published online: 13 Feb 2012
AbstractforMolecular detection of circulating Sezary cells in patients with mycosis fungoides: could it predict future development of secondary Sezary syndrome? A single-institution experience | Full Text | References | PDF (587.5 KB) | Supplemental
  • 370 Views
  • 6 CrossRef citations
  • 0Altmetric
Article
Non-relapse mortality in pediatric acute lymphoblastic leukemia: a systematic review and meta-analysis
Esther Blanco, Joseph Beyene, Anne Marie Maloney, Rowena Almeida, Marie-Chantal Ethier, Naomi Winick, Sarah Alexander & Lillian Sung
Pages: 878-885
Published online: 03 Jan 2012
AbstractforNon-relapse mortality in pediatric acute lymphoblastic leukemia: a systematic review and meta-analysis | Full Text | References | PDF (612.9 KB) | Supplemental
  • 475 Views
  • 23 CrossRef citations
  • 0Altmetric
Article
Heterogeneous leukemic clones identified by NPM1 mutation analysis in patient with acute monocytic leukemia
Chun Qiao, Run Zhang, Ming Hong, Li Wang, Jian-Fu Zhang, Yu-Jie Wu, Hai-Rong Qiu, Hong-Xia Qiu, Si-Xuan Qian, Hua Lu, Su-Jiang Zhang & Jian-Yong Li
Pages: 886-890
Published online: 07 Dec 2011
AbstractforHeterogeneous leukemic clones identified by NPM1 mutation analysis in patient with acute monocytic leukemia | Full Text | References | PDF (566.9 KB) | Supplemental
  • 175 Views
  • 7 CrossRef citations
  • 0Altmetric
Article
Comparative outcomes of Thai children with acute lymphoblastic leukemia treated with two consecutive protocols: 11-year experience
Pacharapan Surapolchai, Samart Pakakasama, Nongnuch Sirachainan, Usanarat Anurathapan, Duantida Songdej, Ampaiwan Chuansumrit & Suradej Hongeng
Pages: 891-900
Published online: 03 Jan 2012
AbstractforComparative outcomes of Thai children with acute lymphoblastic leukemia treated with two consecutive protocols: 11-year experience | Full Text | References | PDF (387.3 KB) | Supplemental
  • 364 Views
  • 5 CrossRef citations
  • 0Altmetric
Article
Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant
Stefan O. Ciurea, Rima M. Saliba, Nelson Hamerschlak, Amado J. Karduss Aurueta, Roland Bassett, Marcelo Fernandez-Vina, Demetrios Petropoulos, Laura L. Worth, Ka Wah Chan, Daniel R. Couriel, Gabriela Rondon, Manish Sharma, Muzaffar Qazilbash, Roy B. Jones, Partow Kebriaei, John McMannis, Chitra M. Hosing, Yago Nieto, Richard E. Champlin, Elizabeth J. Shpall & Marcos de Lima
Pages: 901-906
Published online: 03 Jan 2012
AbstractforFludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant | Full Text | References | PDF (278 KB) | Supplemental
  • 433 Views
  • 17 CrossRef citations
  • 0Altmetric
Article
Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis
Franck E. Nicolini, Tamas Masszi, Zhixiang Shen, Neil J. Gallagher, Saengsuree Jootar, Bayard L. Powell, Pedro Enrique Dorlhiac-Llacer, Ming Zheng, Tomasz Szczudlo & Anna Turkina
Pages: 907-914
Published online: 05 Dec 2011
AbstractforExpanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis | Full Text | References | PDF (414.5 KB) | Supplemental
  • 898 Views
  • 23 CrossRef citations
  • 0Altmetric
Article
Randomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplant
Qaiser Bashir, Mark F. Munsell, Sergio Giralt, Leandro de Padua Silva, Manish Sharma, Daniel Couriel, Alexandre Chiattone, Uday Popat, Muzaffar H. Qazilbash, Marcelo Fernandez-Vina, Richard E. Champlin & Marcos J. de Lima
Pages: 915-919
Published online: 05 Dec 2011
AbstractforRandomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplant | Full Text | References | PDF (318.5 KB) | Supplemental
  • 444 Views
  • 24 CrossRef citations
  • 0Altmetric
Article
Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial
Pavel Nemec, Zuzana Zemanova, Petr Kuglik, Kyra Michalova, Jana Tajtlova, Petra Kaisarova, Alexandra Oltova, Hana Filkova, Milena Holzerova, Jana Balcarkova, Marie Jarosova, Jana Rabasova, Martina Hruba, Ivan Spicka, Evzen Gregora, Zdenek Adam, Vlastimil Scudla, Vladimir Maisnar, Miroslava Schutzova, Roman Hajek & The Czech Myeloma Group
Pages: 920-927
Published online: 13 Dec 2011
AbstractforComplex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial | Full Text | References | PDF (393.1 KB) | Supplemental
  • 629 Views
  • 29 CrossRef citations
  • 0Altmetric
Article
Utility values for chronic myelogenous leukemia chronic phase health states from the general public in the United Kingdom
Julian F. Guest, Neepa Naik, Erikas Sladkevicius, John Coombs & Elizabeth J. Gray
Pages: 928-933
Published online: 05 Dec 2011
AbstractforUtility values for chronic myelogenous leukemia chronic phase health states from the general public in the United Kingdom | Full Text | References | PDF (263.6 KB) | Supplemental
  • 144 Views
  • 7 CrossRef citations
  • 0Altmetric
Article
Effect of homoharringtonine on bone marrow CD34 + CD117 + cells in patients with chronic myelogenous leukemia
Yu-Feng Li, Zhikui Deng, Ban-He Din & Jian-Bin Zhu
Pages: 934-939
Published online: 06 Dec 2011
AbstractforEffect of homoharringtonine on bone marrow CD34 + CD117 + cells in patients with chronic myelogenous leukemia | Full Text | References | PDF (262.1 KB) | Supplemental
  • 138 Views
  • 5 CrossRef citations
  • 0Altmetric
Article
Impacts of cytogenetic categories in the Revised International Prognostic Scoring System on the prognosis of primary myelodysplastic syndromes: results of a single-center study
Shiqiang Qu, Zefeng Xu, Yue Zhang, Tiejun Qin, Tianjiao Zhang, Rui Cui & Zhijian Xiao
Pages: 940-946
Published online: 06 Dec 2011
AbstractforImpacts of cytogenetic categories in the Revised International Prognostic Scoring System on the prognosis of primary myelodysplastic syndromes: results of a single-center study | Full Text | References | PDF (361.6 KB) | Supplemental
  • 451 Views
  • 13 CrossRef citations
  • 0Altmetric
Article
Association of genetic variations in mTOR with risk of childhood acute lymphoblastic leukemia in a Chinese population
Lizhen Huang, Jie Huang, Peng Wu, Qian Li, Liucheng Rong, Yao Xue, Qin Lu, Jie Li, Na Tong, Meilin Wang, Zhengdong Zhang & Yongjun Fang
Pages: 947-951
Published online: 05 Dec 2011
AbstractforAssociation of genetic variations in mTOR with risk of childhood acute lymphoblastic leukemia in a Chinese population | Full Text | References | PDF (265.5 KB) | Supplemental
  • 188 Views
  • 20 CrossRef citations
  • 0Altmetric
Article
The T_T genotype within the NME1 promoter single nucleotide polymorphism −835 C/T is associated with an increased risk of cytarabine induced neurotoxicity in patients with acute myeloid leukemia
Dominic Braunagel, Markus Schaich, Michael Kramer, Christian-Lars Dransfeld, Gerhard Ehninger & Ulrich Mahlknecht
Pages: 952-957
Published online: 07 Dec 2011
AbstractforThe T_T genotype within the NME1 promoter single nucleotide polymorphism −835 C/T is associated with an increased risk of cytarabine induced neurotoxicity in patients with acute myeloid leukemia | Full Text | References | PDF (476.1 KB) | Supplemental
  • 267 Views
  • 12 CrossRef citations
  • 0Altmetric

Original Articles: Research

Article
Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens
Laurent Boissel, Monica Betancur, Weiquan Lu, Winfried S. Wels, Teresa Marino, Richard A. Van Etten & Hans Klingemann
Pages: 958-965
Published online: 06 Dec 2011
AbstractforComparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens | Full Text | References | PDF (526.9 KB) | Supplemental
  • 1462 Views
  • 102 CrossRef citations
  • 0Altmetric

Research Article

Article
Protein phosphatase-2A activation is a critical step for enzastaurin activity in chronic lymphoid leukemia cells
Cecile Liffraud, Anne Quillet-Mary, Jean-Jacques Fournié, Guy Laurent & Loic Ysebaert
Pages: 966-972
Published online: 06 Dec 2011
AbstractforProtein phosphatase-2A activation is a critical step for enzastaurin activity in chronic lymphoid leukemia cells | Full Text | References | PDF (481.6 KB) | Supplemental
  • 219 Views
  • 6 CrossRef citations
  • 0Altmetric
Article
Synergistic cytotoxicity of the DNA alkylating agent busulfan, nucleoside analogs and suberoylanilide hydroxamic acid in lymphoma cell lines
Benigno C. Valdez, David Murray, Yago Nieto, Yang Li, Guiyun Wang, Richard E. Champlin & Borje S. Andersson
Pages: 973-981
Published online: 06 Dec 2011
AbstractforSynergistic cytotoxicity of the DNA alkylating agent busulfan, nucleoside analogs and suberoylanilide hydroxamic acid in lymphoma cell lines | Full Text | References | PDF (546 KB) | Supplemental
  • 410 Views
  • 20 CrossRef citations
  • 0Altmetric

Letters to the Editor

Letter
Importance of granulocyte colony-stimulating factor prophylaxis in therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone given every 14 days for diffuse large B-cell lymphoma in routine clinical practice
Hans E. Johnsen, Corrine Haioun, Pieternella J. Lugtenburg, Antonio Salar, Ulrich Jaeger, Ruth Pettengell, Francesca G. Rossi, Gregor Verhoef, Matthias Schwenkglenks, Kate Bendall & Ulrich Duehrsen
Pages: 982-984
Published online: 11 Jan 2012
First Page PreviewforImportance of granulocyte colony-stimulating factor prophylaxis in therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone given every 14 days for diffuse large B-cell lymphoma in routine clinical practice | Full Text | References | PDF (256.6 KB) | Supplemental
  • 234 Views
  • 4 CrossRef citations
  • 0Altmetric

Letter

Letter
Application of French prognostic score to patients with International Prognostic Scoring System intermediate-2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to predict overall survival and rate of response
Massimo Breccia, Giuseppina Loglisci, Laura Cannella, Paola Finsinger, Marco Mancini, Alessandra Serrao, Michelina Santopietro, Adriano Salaroli & Giuliana Alimena
Pages: 985-986
Published online: 11 Jan 2012
CitationforApplication of French prognostic score to patients with International Prognostic Scoring System intermediate-2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to predict overall survival and rate of response | Full Text | References | PDF (220.4 KB) | Supplemental
  • 296 Views
  • 18 CrossRef citations
  • 0Altmetric
Letter
Cutaneous involvement with B-lineage acute lymphoblastic leukemia
Chadi Nabhan, Angelica Tolentino, Andrew Meyer & Martin S. Tallman
Pages: 987-989
Published online: 05 Dec 2011
First Page PreviewforCutaneous involvement with B-lineage acute lymphoblastic leukemia | Full Text | References | PDF (307.1 KB) | Supplemental
  • 121 Views
  • 7 CrossRef citations
  • 0Altmetric
Letter
Clinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed lymphoma
Yasuhiro Oki, Amanda Copeland, Jorge Romaguera, Luis Fayad, Michelle Fanale, Silvana de Castro Faria, L. Jeffrey Medeiros, Percy Ivy & Anas Younes
Pages: 990-992
Published online: 13 Mar 2012
First Page PreviewforClinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed lymphoma | Full Text | References | PDF (343.9 KB) | Supplemental
  • 198 Views
  • 14 CrossRef citations
  • 0Altmetric
Letter
Osteolytic bone lesions as a rare sign of progression of chronic lymphocytic leukemia without evidence of Richter syndrome
Michael Mian, Silvia Cerú, Atto Billio, Carlo Rosanelli & Sergio Cortelazzo
Pages: 993-995
Published online: 07 Dec 2011
First Page PreviewforOsteolytic bone lesions as a rare sign of progression of chronic lymphocytic leukemia without evidence of Richter syndrome | Full Text | References | PDF (252.3 KB) | Supplemental
  • 168 Views
  • 7 CrossRef citations
  • 0Altmetric
Letter
β-Catenin signaling: no relevance in Hodgkin lymphoma?
Kristina Sohlbach, Roland Moll, Jennifer Goßmann, Oxana Nowak, Peter Barth, Andreas Neubauer & Minh Quang Huynh
Pages: 996-998
Published online: 05 Dec 2011
First Page Previewforβ-Catenin signaling: no relevance in Hodgkin lymphoma? | Full Text | References | PDF (345.1 KB) | Supplemental
  • 132 Views
  • 7 CrossRef citations
  • 0Altmetric
Letter
RAS mutations in therapy-related acute myeloid leukemia after successful treatment of acute promyelocytic leukemia
Katalin Kelemen, Tibor Kovacsovics, Rita Braziel, Christopher Corless, Carol Beadling & Guang Fan
Pages: 999-1002
Published online: 07 Dec 2011
First Page PreviewforRAS mutations in therapy-related acute myeloid leukemia after successful treatment of acute promyelocytic leukemia | Full Text | References | PDF (366.4 KB) | Supplemental
  • 145 Views
  • 3 CrossRef citations
  • 0Altmetric
Letter
Posterior reversible encephalopathy syndrome in a patient with multiple myeloma treated with thalidomide
Signy Chow, Christina S. Cheung, Donald H. Lee, Kang Howson-Jan & Anargyros Xenocostas
Pages: 1003-1005
Published online: 06 Dec 2011
First Page PreviewforPosterior reversible encephalopathy syndrome in a patient with multiple myeloma treated with thalidomide | Full Text | References | PDF (282.2 KB) | Supplemental
  • 316 Views
  • 5 CrossRef citations
  • 0Altmetric
Letter
A novel CCAAT/enhancer binding protein α germline variant in a case of acute myeloid leukemia
Jonathan A. Gutman & Brianna Hoffner
Pages: 1006-1007
Published online: 03 Jan 2012
CitationforA novel CCAAT/enhancer binding protein α germline variant in a case of acute myeloid leukemia | Full Text | References | PDF (231.7 KB) | Supplemental
  • 219 Views
  • 7 CrossRef citations
  • 0Altmetric
Letter
Lymphoma mimicking a dental periapical lesion
Renato N. Hopp, Mateus T. Marchi, Michele G. Kellermann, Victor H. T. Rizo, Márcio A. Lopes & Jacks Jorge
Pages: 1008-1010
Published online: 13 Dec 2011
First Page PreviewforLymphoma mimicking a dental periapical lesion | Full Text | References | PDF (376.4 KB) | Supplemental
  • 159 Views
  • 13 CrossRef citations
  • 0Altmetric

Correspondence

Article
Osteolytic bone lesions in non-transformed chronic lymphocytic leukemia are not as rare as suggested
John F. Seymour
Page: 1011
Published online: 31 Jan 2012
CitationforOsteolytic bone lesions in non-transformed chronic lymphocytic leukemia are not as rare as suggested | Full Text | References | PDF (210.4 KB) | Supplemental
  • 121 Views
  • 2 CrossRef citations
  • 0Altmetric

Research Article

Article
Authors' response to Professor J. F. Seymour
Michael Mian & Sergio Cortelazzo
Page: 1012
Published online: 31 Jan 2012
CitationforAuthors' response to Professor J. F. Seymour | Full Text | References | PDF (205.8 KB) | Supplemental
  • 35 Views
  • 0 CrossRef citations
  • 0Altmetric

Explore articles